Moleculin Reports Initial Patients Treated in Phase 2 Trial Combining STAT3 Inhibitor with Radiation for Glioblastoma Therapy.

Boehringer's zongertinib demonstrates promising effectiveness and tolerability in patients with HER2-mutated lung cancer who have undergone prior treatment.

Phanes Therapeutics reported that the first patient has received a dose in the clinical trial of PT886 alongside chemotherapy.

Clear Scientific Reveals Positive Initial Clinical Trial Results for CS-1103, a Novel Treatment for Meth and Fentanyl Overdose.

Ractigen Shares Encouraging Clinical Results for RAG-17 in ALS-SOD1 Therapy from Independent Study.

Insulin efsitora alfa, administered weekly, achieves comparable A1C reduction to daily insulin in adults with type 1 diabetes.

Recent findings on the investigational drug BAY 2927088 for HER2-mutant non-small cell lung cancer (NSCLC) showcased at WCLC.

In the TROPION-Lung01 Phase 3 trial, Datopotamab Deruxtecan demonstrated a median overall survival of 14.6 months for patients with advanced nonsquamous non-small cell lung cancer.

Incendia Therapeutics Begins Phase 1c Trial with First Patient for PRTH-101, an Innovative DDR1 Inhibitor.

Viridian Therapeutics Reports Encouraging Topline Results from Phase 3 THRIVE Trial of Veligrotug (VRDN-001) in Thyroid Eye Disease Patients.

Basking Biosciences Administers Initial Dosage to Participants in Phase 2 Study of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke.

TILT Biotherapeutics Unveils TILT-123 Clinical Results After Complete IV Administration at ESMO 2024.